Please assess the completion status of the following clinical trial:

Trial Title: Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with clinically proved superficial bladder cancer (Ta G1/G2 or T1G1/G2) 2 - 7 weeks before transurethral resection~* Written informed consent for study participation and for documentation of disease data including further distribution of these data~Exclusion Criteria:~* Muscle invasive bladder carcinoma and/or carcinoma in situ (CIS)~* Intravesical instillation therapy within 6 months prior to study enrolment~* Radiotherapy of the bladder prior to study enrolment~* Contracted bladder (capacity less than 100 ml)~* Non treated acute or chronic urinary tract infection~* Allergy against mistletoe extract preparations~* Subvesical obstructions (e. g. prostate hyperplasia, urethral stenosis, residual urine volume more than 80 ml)~* Severe illnesses and circumstances not permitting study participation (e. g. alcoholism or substance abuse)~* Pregnancy or lactation (pregnancy test if required) as well as women without sufficient contraception~* Participation in another clinical study within 30 days prior to this study~* Administration of immunotherapeutic and/or cytostatic drugs within 4 weeks prior to study enrolment~* Chronic progressive infections (e. g. tuberculosis)~* Pre-treatment with mistletoe extracts/mistletoe lectins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dose escalation (Type: EXPERIMENTAL): intravesical instillation of abnobaVISCUM Fraxini

Based on this trial design, predict the completion outcome and termination type (if applicable).